Original research
par
Corace, Kim et al
Date de publication
2021
Géographie
Canada
Langue de la ressource
English
Texte disponible en version intégrale
Non
Open Access / OK to Reproduce
Non
Évalué par des pairs
Yes
L’objectif
The Ontario COVID-19 OAT Treatment Guidance document was developed to facilitate access to OAT and continuity of care during the pandemic, while supporting physical distancing measures. In particular, the Guidance expanded access to unsupervised OAT dosing. It is important to evaluate the changes in unsupervised OAT dosing after the release of the Ontario COVID-19 OAT Guidance based on patients’ and prescribers’ reports.
Constatations/points à retenir
Many patients (57%) reported receiving additional unsupervised OAT doses (i.e., take away doses). Patients who received additional unsupervised doses were not significantly more likely to report adverse health outcomes compared to patients who did not receive additional unsupervised doses. Patients with additional unsupervised doses and prescribers agreed that changes in OAT care were positive (e.g., reported an improved patient-prescriber relationship and more openness between patient and prescriber). Prescribers and some patients reported the need for continued flexibility in unsupervised doses after the pandemic restrictions lift.
La conception ou méthodologie de recherche
Patients (N=402) and prescribers (N=100) reported their experiences with changes in unsupervised dosing during the first six months of the pandemic.
Mots clés
Evidence base
Policy/Regulatory
Hesitancy of prescribers
Safer supply
Advocacy
About prescribers
About PWUD
Substitution/OAT
